CUE - Cue Biopharma Operating income before deduction of amortization

Public company logo of Cue Biopharma, Inc. (CUE)

The EBITDA growth trajectory demonstrates the operational income dynamics of Cue Biopharma, Inc. (CUE). Immuno-STAT technology enables the targeted activation of T-cells within tumors while avoiding systemic inflammation. The development of treatments for infections and cancer expands the startup's therapeutic capabilities. The absence of sales renders profit independent of pricing, and the 0.00 mark reflects the latest data on the business's liquidity.

CUE Cue Biopharma Profit before payment of interest, taxes and amortization (11/23/2025 - 11/12/2026)

Summary analytical data breakdowns for Cue Biopharma, Inc. (CUE)

- stock quotes and analyst forecast:
Price Performance Chart Cue Biopharma Inc.|CUE - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Cue Biopharma|CUE - Total Company Value
- balance sheet equity data:
Accounting Value per Share Cue Biopharma|CUE - Company Book Value|Market Cap to Net Assets Ratio cuebiopharma.com|CUE - Cumulative Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Cue Biopharma, Inc.|CUE - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio cuebiopharma.com|CUE - Company Debts|Debts to Book Value Cue Biopharma|CUE - Company Long-Term Liabilities|Short-Term Indebtedness Cue Biopharma|Intermediate Liquidity Ratio cuebiopharma.com
- earnings and multiples data:
CUE - Net Profit|Expected Net Income Cue Biopharma, Inc.|CUE - P/E Multiple|Projected Price to Earnings Ratio Cue Biopharma Inc.|CUE - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Cue Biopharma|CUE - Operating profit EBITDA|Net earnings per share (EPS TTM) Cue Biopharma|CUE - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months cuebiopharma.com|CUE - Net earnings per share growth this year|Expected net earnings per share growth next year Cue Biopharma, Inc.
Analysis of all company metrics:Cue Biopharma, Inc.
Original product of Cue Biopharma Inc.

This indicator tracks the daily inflow of actual cash from core operations, excluding the impact of taxes and depreciation to assess net operating cash flow. By analyzing the trend of operating profit before taxes, an investor can see the efficiency of the Cue Biopharma, Inc. (CUE) Immuno-STAT platform, where the scalability of selective immunotherapy minimizes costs for new targets, optimizing capital-intensive R&D expenses.

Competitor analysis for Cue Biopharma, Inc.

Income before deduction of interest, taxes and amortization IBRX|Immunocore Holdings plc - Operating profit EBITDA|Operating income before deduction of amortization januxrx.com JANX|Arcus Biosciences (RCUS) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Zymeworks Inc|Profit before payment of interest, taxes and amortization Tango Pharma|Operating profit before deduction of amortization Iovance Corp (IOVA)|Operating profit before deduction of amortization IMTX (Immatics N.V.)|Operating profit EBITDA xencor.com (XNCR)|Profit before payment of interest, taxes and amortization Compass Therapeutics, Inc. CMPX|REPL: Operating profit before amortization|LYEL - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Innate Pharma S.A|PYXS (pyxisoncology.com) - Operating profit before deduction of amortization|Operating profit before depreciation charges Compugen CGEN|Operating profit before deduction of amortization IOBT|STRO (Sutro Biopharma Inc.) - Company profit before taxes, interest and amortization|Operating profit EBITDA INKT|HOWL (werewolftx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA IMMX (Immix Biopharma)|ALX Oncology Holdings Inc. (ALXO) - Profit before interest, taxes and amortization|PDSB - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization SONN (Sonnet BioTherapeutics)|MAIA: Operating profit EBITDA|Liminatus (LIMN) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization LAVA Therapeutics NV|nextcure.com - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit before deduction of amortization LPTX (Leap Therapeutics, Inc.)|INTS - Profit before interest, taxes and amortization|Operating profit EBITDA SNSE (Sensei Biotherapeutics, Inc.)|TOVX - Operating profit before deduction of amortization|GRTS: Operating profit before deduction of amortization|KA - Operating profit EBITDA|NEXI: Operating profit EBITDA|Profit before interest, taxes and amortization Turnstone Biologics Corp. (TSBX)|Operating profit before deduction of amortization VCNX|HARP: Income before deduction of interest, taxes and amortization